Tirzepatide

Tirzepatide is a synthetic 39-amino-acid fatty-acid-acylated peptide engineered as a dual agonist of the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R), a pharmacological architecture sometimes termed a "twincretin" because it simultaneously activates both major incretin hormone receptors. The molecule was developed by Eli Lilly and Company and has received FDA approval under the brand names Mounjaro (type 2 diabetes mellitus, approved May 2022) and Zepbound (chronic weight management, approved November 2023), making tirzepatide the first approved dual incretin receptor agonist in clinical medicine. Its research significance extends well beyond its approved indications: the simultaneous activation of two mechanistically distinct receptors allows investigators to dissect how GIP and GLP-1 signaling pathways interact, overlap, and produce emergent metabolic effects that neither pathway produces alone.

Structural and Chemical Properties

Tirzepatide's sequence is based on native GIP but incorporates modifications that confer GLP-1R agonism, proteolytic stability, and favorable pharmacokinetics. The peptide bears a C20 fatty-diacid moiety attached via a linker to lysine at position 26, enabling reversible binding to serum albumin that extends the plasma half-life to approximately five days and permits once-weekly subcutaneous administration. The fatty-acid modification mirrors the approach used in semaglutide but is tuned for dual receptor engagement rather than exclusive GLP-1R potency. Structurally, tirzepatide has roughly equivalent GIP receptor efficacy and slightly lower (approximately one-fifth) intrinsic GLP-1R efficacy compared with native GLP-1, yet it produces superior weight and glycemic outcomes in head-to-head trials against maximum-dose semaglutide — an observation that has focused research attention on understanding exactly how GIPR signaling contributes to the composite pharmacodynamic profile.

The molecular formula is C₂₂₅H₃₄₈N₄₈O₆₈ with a molecular weight of approximately 4,813.5 daltons. CAS number: 2023788-19-2. Peptide purity in research-grade material is typically reported at ≥98% by HPLC. The compound is typically lyophilized and stored at −20°C with reconstitution in bacteriostatic water, sterile water, or PBS for in vitro and in vivo laboratory use.

Mechanism of Action: Dual Incretin Receptor Co-Agonism

GLP-1 receptor agonism activates the canonical incretin pathway: upon glucose ingestion, GLP-1R signaling on pancreatic beta cells amplifies glucose-dependent insulin secretion through cAMP/PKA and Epac2, suppresses glucagon from alpha cells, delays gastric emptying, and signals centrally via the hypothalamus and brainstem to reduce appetite and food intake. These GLP-1-mediated effects have been exploited clinically by the class of single-agonist GLP-1RAs including liraglutide, semaglutide, and dulaglutide.

GIPR activation adds a separate and complementary dimension. GIP is secreted primarily from duodenal K-cells and potentiates insulin secretion through its own cAMP pathway with a profile that is maximally active in the postprandial state. Beyond the pancreas, GIPR expression in adipose tissue, the central nervous system (particularly the hypothalamus, ventromedial nucleus, and hindbrain), and bone modulates fat partitioning, energy expenditure, and potentially the tolerance to GLP-1R-mediated nausea. Preclinical data suggest that GIPR agonism in the CNS reduces food intake via pathways partially distinct from GLP-1R signaling, while adipose GIPR signaling facilitates fatty acid uptake and storage in a context-dependent manner. The net outcome of combined GIPR+GLP-1R co-agonism appears to be greater-than-additive weight reduction and comparable-or-superior glycemic improvement relative to selective GLP-1RAs at maximum doses.

Pharmacokinetics and Dosing in Research Models

After subcutaneous injection, tirzepatide undergoes proteolytic degradation by dipeptidyl peptidase-4 (DPP-4) at the N-terminus and endopeptidases along the backbone, though its acylation markedly slows these processes. Mean absolute bioavailability after subcutaneous injection is approximately 80%. Peak plasma concentrations are reached within approximately 8–72 hours depending on injection site and formulation. Volume of distribution is approximately 10.3 L, reflecting predominant distribution in plasma and extracellular fluid. Albumin binding buffers rapid clearance and contributes to the once-weekly dosing feasibility.

In rodent models, intraperitoneal or subcutaneous doses in the range of 0.1–10 nmol/kg have been used to probe receptor occupancy, glucose tolerance (OGTT/IPGTT), and body composition endpoints. Researchers comparing tirzepatide to semaglutide or retatrutide in the same in vivo model should note that dose-response relationships differ across compounds due to receptor binding kinetics and selectivity profiles, requiring independent curve establishment per compound. In vitro receptor binding assays typically use the peptide at nanomolar concentrations; competitive binding constants (Ki) against radiolabeled GIP and GLP-1 are available in the primary pharmacology literature.

Clinical Evidence Base (Research Background)

The SURMOUNT program of clinical trials has comprehensively characterized tirzepatide's weight-reduction effects. SURMOUNT-1 (NCT04184622, n=2,519, 72 weeks, tirzepatide 5/10/15 mg weekly vs. placebo) showed mean weight reductions of 15.0%, 19.5%, and 20.9% respectively versus 3.1% for placebo, with 57% of participants at the highest dose achieving ≥20% weight loss. SURMOUNT-2 enrolled adults with type 2 diabetes and obesity, demonstrating 12.8% to 14.7% weight loss. SURMOUNT-3 used a 12-week intensive lifestyle intervention run-in followed by tirzepatide, showing up to 26.6% total weight loss from enrollment (18.4% from randomization). SURMOUNT-4 examined weight maintenance: participants who lost weight on tirzepatide during a 36-week lead-in and then continued tirzepatide maintained an additional 5.5% loss versus 14.0% regain in the placebo arm.

The SURPASS program addressed glycemic management. SURPASS-2 (head-to-head, n=1,879, 40 weeks) compared tirzepatide 5/10/15 mg to semaglutide 1 mg and demonstrated superior HbA1c reduction (−2.09/−2.37/−2.46% vs. −1.86%) and superior weight loss (−7.8/−10.3/−12.4 kg vs. −6.2 kg). This head-to-head evidence base makes tirzepatide a critical reference compound in clinical pharmacology research examining the incretin axis. SURMOUNT-OSA (sleep apnea subset) found significant reductions in AHI and high rates of sleep apnea resolution, adding cardiorespiratory endpoints to tirzepatide's research landscape.

Research Applications in Laboratory Settings

Dual incretin receptor biology and co-agonism signaling: The mechanistic question of how GIPR and GLP-1R co-activation produces synergistic metabolic outcomes remains an active area of investigation. Researchers using tirzepatide alongside selective GIP and GLP-1 receptor agonists and antagonists (e.g., GIP(3-30)NH₂ as a GIPR antagonist) can map which endpoints are GLP-1R-dependent, which are GIPR-dependent, and which require simultaneous engagement. Signal transduction studies using cAMP reporters, beta-arrestin recruitment assays, and receptor internalization assays with tirzepatide vs. monoagonists illuminate biased signaling and receptor trafficking.

Obesity and energy homeostasis research: Tirzepatide is among the most effective peptide research tools for inducing weight loss in diet-induced obese (DIO) rodent models and for studying the central and peripheral circuits that mediate hyperphagia, adipogenesis, and energy expenditure. Hypothalamic injection studies, vagal nerve recording experiments, and circuit-mapping approaches using tirzepatide help localize GIPR/GLP-1R-sensitive nodes. Pair-feeding controls and measurement of oxygen consumption/respiratory exchange ratio help distinguish caloric restriction effects from direct thermogenic or energetic effects of dual incretin signaling.

Metabolic dysfunction-associated steatotic liver disease (MASLD/MASH): Both receptors are expressed in hepatocytes and hepatic stellate cells, and tirzepatide's improvement in NASH-related endpoints (liver fat on MRI-PDFF, liver enzymes, histological scoring) observed in early clinical data has stimulated preclinical mechanistic work. In vitro studies with primary hepatocytes and hepatic stellate cell lines treated with tirzepatide (with and without receptor-selective antagonists) help determine how much of the hepatoprotective effect is direct vs. indirect (through insulin sensitization, adipokine normalization, and weight loss).

Comparative agonist pharmacology: The availability of semaglutide (GLP-1 selective), tirzepatide (dual GIP/GLP-1), and retatrutide (triple GIP/GLP-1/glucagon) as research materials allows systematic comparison of dose-matched agonism across the incretin/glucagon receptor triad. Tirzepatide serves as the dual-agonist reference point in this three-way comparison, enabling researchers to isolate the contribution of glucagon receptor agonism (present in retatrutide but absent in tirzepatide) to weight loss, hepatic fat clearance, and energy expenditure.

Beta-cell biology and preservation: Beyond acute insulin secretion, tirzepatide's effects on beta-cell proliferation, apoptosis prevention, and functional reserve in diabetes models are under active investigation. In vitro and islet ex vivo work with tirzepatide characterizes receptor-mediated trophic signaling distinct from acute secretagogue activity.

Adipose tissue and lipid metabolism: GIPR expression in white adipose tissue and the depot-specific effects of GIPR agonism on triglyceride synthesis, lipolysis, and adipokine secretion are studied using tirzepatide alongside receptor-selective probes in isolated adipocyte preparations and adipose explant culture systems.

Storage and Handling (Research Grade)

Lyophilized tirzepatide should be stored at −20°C and protected from repeated freeze-thaw cycles. Once reconstituted, solutions should be aliquoted and stored at 4°C for short-term use (up to 7 days) or flash-frozen at −80°C for longer storage. Reconstitution in 1% acetic acid followed by dilution into PBS maintains solubility at working concentrations. Researchers should verify peptide integrity by analytical HPLC and mass spectrometry (expected [M+4H]⁴⁺ at approximately m/z 1204) prior to critical in vivo studies.

Pricing and Supplier Landscape

Peptides.so currently tracks 57 supplier listings for research-grade tirzepatide, providing researchers with a broad view of per-mg pricing and available concentrations/formulations across the peptide research supply market.

Cited Research

Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. PubMed PMID: 35658024.

Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385(6):503-515. PubMed PMID: 34170647.

Dahl D, Onishi Y, Norwood P, et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients with Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA. 2022;327(6):534-545. PubMed PMID: 35133415.

Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232 (comparative reference for SURPASS-CVOT context). PubMed PMID: 37952131.

Samms RJ, Coghlan MP, Sloop KW. How May GIP Enhance the Therapeutic Efficacy of GLP-1? Trends Endocrinol Metab. 2020;31(6):410-421. PubMed PMID: 32396837.

For laboratory research use only. Not for human or veterinary use, diagnosis, treatment, cure, or prevention of any disease. THIS PRODUCT IS NOT FOR HUMAN CONSUMPTION.